CD274 and neoplasm: The benefit of immunotherapy has been largely driven by a subset of patients experiencing durable tumor responses: overall, about 15% to 60% of patients respond to immunotherapy-based approaches, depending on tumor type, tumor mutational burden features (e.g., DNA mismatch repair-deficient [dMMR]/microsatellite instability-high [MSI-H]) and PD-L1 expression levels [1–3].